{"id":"edaravone-dexborneol","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Edaravone acts as a potent free radical scavenger, particularly targeting hydroxyl radicals and peroxynitrite that accumulate during ischemic stroke. Dexborneol, a monoterpene alcohol, enhances neuroprotection by improving microcirculation and reducing cerebral edema. Together, they work synergistically to limit ischemic damage and promote neurological recovery in acute stroke.","oneSentence":"Edaravone Dexborneol is a combination of a free radical scavenger and a borneol-based neuroprotective agent that reduces oxidative stress and improves cerebral blood flow.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:45:14.905Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke"}]},"trialDetails":[{"nctId":"NCT07454473","phase":"PHASE4","title":"Edaravone and Dexborneol Sublingual Tablet for Treating Chemotherapy- Induced Cognitive Impairment Study","status":"RECRUITING","sponsor":"Chuansheng Zhao","startDate":"2026-03-02","conditions":"Chemo Brain","enrollment":80},{"nctId":"NCT06674460","phase":"PHASE3","title":"Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-08-01","conditions":"Cerebral Small Vessel Disease, Ischemic Stroke","enrollment":600},{"nctId":"NCT06315231","phase":"PHASE2","title":"Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients","status":"RECRUITING","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2024-04-08","conditions":"Post-stroke Cognitive Impairment","enrollment":226},{"nctId":"NCT07091994","phase":"PHASE4","title":"A Prospective, Multicentre, Randomized Controlled Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-08-01","conditions":"Ischemic Stroke, Acute, Active Malignancies","enrollment":144},{"nctId":"NCT06645522","phase":"PHASE4","title":"Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Yi Yang","startDate":"2024-10-30","conditions":"Acute Ischemic Stroke","enrollment":1200},{"nctId":"NCT06248242","phase":"PHASE4","title":"Treatment of Acute Ischemic Stroke With Rt-PA Combined With Edaravone Dexborneol","status":"UNKNOWN","sponsor":"The Second Hospital of Hebei Medical University","startDate":"2021-06-01","conditions":"Acute Ischemic Stroke","enrollment":400},{"nctId":"NCT06176781","phase":"PHASE3","title":"The Efficacy and Safety of Edaravone Dexborneol Sequential Therapy in the Treatment of Patients With AIS","status":"UNKNOWN","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2023-12-28","conditions":"Subjects With Acute Ischemic Stroke","enrollment":880},{"nctId":"NCT05644223","phase":"","title":"Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"Xuanwu Hospital, Beijing","startDate":"2023-01-01","conditions":"Acute Ischemic Stroke","enrollment":4750},{"nctId":"NCT05121883","phase":"","title":"Edaravone Dexborneol Combining With Mechanical Thrombectomy in the Treatment of Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-11-01","conditions":"Stroke","enrollment":200},{"nctId":"NCT05249920","phase":"PHASE3","title":"Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2022-03-18","conditions":"Acute Ischemic Stroke, Mechanical Thrombectomy, Edaravone Dexborneol","enrollment":1362},{"nctId":"NCT05953103","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Different Doses of Edaravone Dexborneol Concentrated Solution for Injection Combined With Conventional Medical Therapy in the Treatment of Patients With Cerebral Hemorrhage","status":"UNKNOWN","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2023-07-03","conditions":"Subjects With Cerebral Hemorrhage","enrollment":380},{"nctId":"NCT05885919","phase":"PHASE3","title":"Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2023-07-01","conditions":"Ischemic Stroke, Acute, Treatment Outcome","enrollment":212},{"nctId":"NCT04667637","phase":"PHASE2","title":"Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol","status":"COMPLETED","sponsor":"Hui-Sheng Chen","startDate":"2021-02-23","conditions":"Stroke, Endovascular Thrombectomy","enrollment":200},{"nctId":"NCT04817527","phase":"PHASE2","title":"Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2021-10-01","conditions":"Stroke, Ischemic","enrollment":200},{"nctId":"NCT05024526","phase":"NA","title":"Protective Effects of Edaravone Dexborneol","status":"UNKNOWN","sponsor":"Lili Cao","startDate":"2021-04-01","conditions":"Acute Ischemic Stroke","enrollment":80},{"nctId":"NCT05035953","phase":"PHASE2","title":"Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2021-09-13","conditions":"Stroke, Ischemic","enrollment":200},{"nctId":"NCT04714177","phase":"PHASE2","title":"Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage","status":"UNKNOWN","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2021-03-01","conditions":"Intracerebral Hemorrhage","enrollment":390}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":80,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["edaravone deborbeol placebo","Xian Bi Xin placebo"],"phase":"marketed","status":"active","brandName":"Edaravone Dexborneol","genericName":"Edaravone Dexborneol","companyName":"First Affiliated Hospital, Sun Yat-Sen University","companyId":"first-affiliated-hospital-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Edaravone Dexborneol is a combination of a free radical scavenger and a borneol-based neuroprotective agent that reduces oxidative stress and improves cerebral blood flow. Used for Acute ischemic stroke.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}